{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:04:21Z","timestamp":1792839861903,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23 K16642"],"award-info":[{"award-number":["23 K16642"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jneuroim.2025.578737","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T15:51:01Z","timestamp":1756223461000},"page":"578737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comparison of prednisolone monotherapy vs. tacrolimus combination in NMOSD: Efficacy, safety, and optimal therapeutic timing"],"prefix":"10.1016","volume":"408","author":[{"given":"Keito","family":"Ishihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamichi","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nakamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhide","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2025.578737_bb0005","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000640","article-title":"Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence","volume":"7","author":"Akaishi","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2025.578737_bb0010","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41598-017-00860-y","article-title":"Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jneuroim.2025.578737_bb0015","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458514525870","article-title":"Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2025.578737_bb0020","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2169\/internalmedicine.51.7465","article-title":"Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study","volume":"51","author":"Ikeda","year":"2012","journal-title":"Intern. Med."},{"key":"10.1016\/j.jneuroim.2025.578737_bb0025","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1212\/CON.0000000000000337","article-title":"Neuromyelitis optica spectrum disorders","volume":"22","author":"Katz Sand","year":"2016","journal-title":"Continuum (Minneap Minn)."},{"key":"10.1016\/j.jneuroim.2025.578737_bb0030","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.7164\/antibiotics.40.1249","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics","volume":"40","author":"Kino","year":"1987","journal-title":"J. Antibiot. (Tokyo)."},{"key":"10.1016\/j.jneuroim.2025.578737_bb0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","article-title":"Present and future therapies in neuromyelitis optica spectrum disorders","volume":"13","author":"Kleiter","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jneuroim.2025.578737_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101907","article-title":"Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody","volume":"39","author":"Kojima","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2025.578737_bb0045","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jnnp.2004.042176","article-title":"Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus)","volume":"76","author":"Konishi","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2025.578737_bb0050","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2025.578737_bb0055","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2025.578737_bb0060","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pediatrneurol.2017.08.014","article-title":"Tacrolimus improves symptoms of children with myasthenia gravis refractory to prednisone","volume":"77","author":"Liu","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578737_bb0065","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10067-012-2044-y","article-title":"Effects of tacrolimus on dermatomyositis and polymyositis: a prospective, open, non-randomized study of nine patients and a review of the literature","volume":"31","author":"Matsubara","year":"2012","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jneuroim.2025.578737_bb0070","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/s10165-008-0071-y","article-title":"Efficacy of low-dose tacrolimus added to methotrexate in patients with rheumatoid arthritis in Japan: a retrospective study","volume":"18","author":"Morita","year":"2008","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.jneuroim.2025.578737_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105829","article-title":"Clinical practice guidelines for multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease 2023 in Japan","volume":"90","author":"Niino","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2025.578737_bb0080","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of neuromyelitis optica: a systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2025.578737_bb0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bpobgyn.2019.09.002","article-title":"Pregnancy and systemic lupus erythematosus","volume":"64","author":"Petri","year":"2020","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"10.1016\/j.jneuroim.2025.578737_bb0090","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40120-021-00253-4","article-title":"Neuromyelitis optica spectrum disorder: clinical burden and cost of relapses and disease-related care in US clinical practice","volume":"10","author":"Royston","year":"2021","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.jneuroim.2025.578737_bb0095","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2025.578737_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102750","article-title":"Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy","volume":"49","author":"Takai","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2025.578737_bb0105","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1177\/1352458514546793","article-title":"Corticosteroid and tacrolimus treatment in neuromyelitis optica related disorders","volume":"21","author":"Tanaka","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2025.578737_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102707","article-title":"Low-dose tacrolimus in treating neuromyelitis optica spectrum disorder","volume":"48","author":"Wang","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2025.578737_bb0115","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/1352458507077189","article-title":"Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2025.578737_bb0120","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International panel for NMO diagnosis, international consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2025.578737_bb0125","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825002188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825002188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:35:00Z","timestamp":1782261300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572825002188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":25,"alternative-id":["S0165572825002188"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578737","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of prednisolone monotherapy vs. tacrolimus combination in NMOSD: Efficacy, safety, and optimal therapeutic timing","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578737","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"578737"}}